Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury

American Journal of Medicine

Volumn 101, Issue 1 A, 1996, Pages S25-S32

  Bjorkman, David J ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; DIGESTIVE SYSTEM INJURY; DRUG CHOICE; DRUG COST; DRUG EFFECT; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH INSURANCE; HUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029758444     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)90032-7     Document Type: Review

References (88)

1. Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. (Editorial.) Ann Intern Med. 1988;109:353-354.
2. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum. 1989;32:926-932.
3. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41-47.
4. Langman MJ. Epidemiologic evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology. 1989;96(2 pt 2 Suppl):640-646.
5. Pincus T, Griffin M. Gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs: new insights from observational studies and functional status questionnaires. Am J Med. 1991;91:209-212.
6. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenrerol. 1987;82:1153-1158.
7. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527-532.
8. Lockard OO Jr, Ivey KJ, Butt JH, Silvoso GR, Sisk C, Holt S. The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc. 1980;26:5-7.
9. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-222.
10. Bjarnason I, Hayllar J, Macherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847.
11. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749-754.
12. Bjarnason I, Price AB, Zanelli G, et al. Clinicopathological features of nonsteroidal anti-inflammatory drug-induced small intestinal stricture. Gastroenterology. 1988;94:1070-1074.
13. Isenberg JI. Overview of clinical cytoprotection. Dig Dis Sci. 1985;30(Suppl 11):81S-82S.
14. Wilson DE. Role of prostaglandins in gastroduodenal mucosal protection. J Clin Gastroenterol. 1991;13(Suppl 1):S65-S71.
15. Soil AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307-319.
16. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245:G601-G623.
17. Davenport HW. Damage to the gastric mucosa: effects of salicylates and stimulation. Gastroenterology. 1965;49:189-196.
18. McCarthy DM. Nonsteroidal anti-inflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology. 1989;96(2 pt 2 Suppl):662-674.
19. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci. 1983;28:1-6.
20. Wallace JL. Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin North Am. 1992;21:631-641.
21. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-869.
22. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990;259:G462-G467.
23. Wallace JL, Hogaboam CM, Kubes P. Immunopathology of NSAID-gastropathy: inhibitory effects of interleukin-I and cyclosporin A. Ann NY Acad Sci. 1992;664:400-407.
24. Hawkey CJ. Non-steroidal anti-inflammatory drugs and the gastric mucosa: mechanisms of damage and protection. Aliment Pharmacol Ther. 1988;2(Suppl 1):57-64.
25. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation. 1992;16:227-240.
26. Lanza FL, Karlin DA, Yee JP. A double-blind placebo-controlled endoscopic study comparing the mucosal injury seen with an orally and parenterally administered new nonsteroidal analgesic ketorolac tromethamine at therapeutic and supratherapeutic doses. (Abstr.) Am J Gastroenterol. 1987;82:939.
27. Lanza FL, Umbenhauer ER, Nelson RS, Rack MF, Daurio CP, White LA. A double-blind randomized placebo-controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumatol. 1982;9:415-419.
28. Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol. 1994;89:203-207.
29. Gubbins GP, Schubert TT, Attanasio F, Lubetsky M, Perez-Perez GI, Blaser MJ. Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal anti-inflammatory drugs and gold compounds. Am J Med. 1992;93:412-418.
30. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol. 1992;87:1398-1402.
31. Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991;100:1653-1657.
32. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989;11:158-162.
33. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983;74:820-828.
34. Bijlsma JW. Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. Aliment Pharmacof Ther. 1988;2(Suppl 1):75-83.
35. Caldwell JR, Roth SH, Wu WC, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med. 1987;83(Suppl 3B):74-82.
36. Himal HS. Benign cecal ulcer. Surg Endosc. 1989;3:170-172.
37. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnason I. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol. 1988;41:516-526.
38. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-516.
39. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs: report of four cases and review of the literature. Arch Intern Med. 1992;152:625-632.
40. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979;91:517-520.
41. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
42. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J. 1990;300:278-284.
43. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986;i:462-464.
44. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet. 1986;i:489-492.
45. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a metaanalysis. Ann Intern Med. 1991;115:787-796.
46. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987;147:85-88.
47. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med. 1992;152:1145-1155.
48. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
49. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
50. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
51. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and hemorrhage. Br Med J Clin Res Ed. 1985;290:347-349.
52. Heller SR, Fellows IW, Ogilvie AL, Atkinson M. Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. Br Med J Clin Res Ed. 1982;285:167-168.
53. Wilkins WE, Ridley MG, Pozniak AL. Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs. Gut. 1984;25:478-480.
54. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterotogy. 1992;102:139-148.
55. Collins AJ, Davies J, Dixon SA. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs and a general population referred for endoscopy. Br J Rheumatol. 1986;25:50-53.
56. Pye G, Ballantyne KC, Armitage NC, Hardcastle JD. Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer. Br Med J Clin Res Ed. 1987;294:1510-1511.
57. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87-91.
58. Manniche C, Malchow-Moller A, Andersen JR, et al. Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut. 1987;28:226-229.
59. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut. 1991;32:252-255.
60. Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989;320:69-75.
61. Roth S, Agrawal N, Mahowald M, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med. 1989;149:775-779.
62. Sontag SJ, Schnell TG, Budiman-Mak E, et al. Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil). Am J Gastroenterol. 1994;89:1014-1020.
63. Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum. 1993;36:84-90.
64. Roth S, Bennett R, Caldron P, et al. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsatate): an endoscopic study. Serran Arthritis Rheum. 1990;19(4 Suppl 2):11-19.
65. The Multicenter Salsalate/Aspirin Comparison Study Group. Does the acetyl group of aspirin contribute to the anti-inflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? J Rheumatol. 1989;16:321-327.
66. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol. 1993;88:1318-1323.
67. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
68. Tana AS, McLaughlin S, Sturrock RD, Russell RI. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol. 1989;28:329-332.
69. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995;42:428-433.
70. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
71. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med. 1993;95(Suppl 2A):40S-44S.
72. Lanueville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
73. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994;107:173-179.
74. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995;109:524-530.
75. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;ii:1277-1280.
76. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med. 1993;119:257-262.
77. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
78. Elliott SL, Yeomans ND, Buchanan RRC, et al. Long term effects of misoprostol on gastropathy induced by nonsteroidal anti-inflammatory drugs (NSAID). (Abstr.) Gastroenterology. 1990;98:A40.
79. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J. 1988;297:1017-1021.
80. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34:424-428.
81. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993;153:2449-2454.
82. Taha AS, Hudson N, Trye P, et al. Prevention of NSAID-related gastric and duodenal ulcers by famotidine: a placebo-controlled double-blind study. (Abstr.) Gastroenterology. 1994;106:A190.
83. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut. 1990;31:514-517.
84. Oddsson E, Gudjonsson H, Thjodleifsson B. Protective effect of omeprazole or ranitidine against naproxen induced damage to the human gastroduodenal mucosa. Scand J Gastroenterol. 1990;25(Suppl 176):A13.
85. Dorta G, Saraga E, Nicolet M, et al. Influence of omeprazole (OME) on healing and prevention of gastroduodenal mucosal lesions during administration of NSAIDs. (Abstr.) Gastroenterology. 1991;100:A55.
86. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med. 1991;115:195-200.
87. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84(Suppl 2A):20-24.
88. Levine JS. Misoprostol and nonsteroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs. Ann Intern Med. 1995;123:309-310.